Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC

NCT04557020 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: PD-1 antibody
DRUG: Gemcitabine
DRUG: Cisplatin
RADIATION: IMRT

Sponsor

Jiangxi Provincial Cancer Hospital